

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

27 May 2026

### Comparison of the effectiveness of maintenance doses of caffeine citrate on tracheal tube removal and apnea after it in premature infants

#### Protocol summary

##### Study aim

Comparison of the effectiveness of maintenance doses of caffeine citrate on tracheal tube removal and apnea after it in premature neonates

##### Design

The clinical trial with parallel groups, one blind strain, randomized in two groups, phase 2-3 is performed on 80 babies. The rand function of Excel software is used for randomization.

##### Settings and conduct

A single-blind interventional study is conducted on infants hospitalized in the neonatal intensive care unit of Afzalipur Hospital in Kerman, who meet the conditions for entering the study. After the random allocation and receiving the medicine, the babies are examined and the primary and secondary outcomes are checked and recorded.

##### Participants/Inclusion and exclusion criteria

Entry conditions: neonates with a gestational age of less than 35 weeks and hemodynamic stability during the first 48 hours after mechanical ventilation. Conditions of non-entry: neonates with congenital obstruction and perforation of the gastrointestinal tract, gastroschisis, congenital diaphragmatic hernia, cyanotic heart diseases and other congenital anomalies.

##### Intervention groups

The first group are infants who are treated with caffeine citrate with an initial dose of 20 mg per kilogram of weight per day and a maintenance dose of 10 mg per kilogram of weight per day until the infant does not experience apnea at least 7 days after extubation. are placed (group with high maintenance dose). The second group are infants who receive caffeine citrate with an initial dose of 20 mg per kilogram of body weight per day and a maintenance dose of 5 mg per kilogram of body weight per day until the infant does not experience apnea at least 7 days after extubation.

##### Main outcome variables

Tracheal extubation failure and subsequent apnea

#### General information

##### Reason for update

End of sampling

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20230408057850N1**

Registration date: **2023-04-17, 1402/01/28**

Registration timing: **prospective**

Last update: **2023-08-01, 1402/05/10**

Update count: **1**

##### Registration date

2023-04-17, 1402/01/28

##### Registrant information

##### Name

zahra daei parizi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 34 3325 7469

##### Email address

zdae@kmu.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2023-04-21, 1402/02/01

##### Expected recruitment end date

2023-07-23, 1402/05/01

##### Actual recruitment start date

2023-04-21, 1402/02/01

##### Actual recruitment end date

2023-07-11, 1402/04/20

##### Trial completion date

2023-07-24, 1402/05/02

## Scientific title

Comparison of the effectiveness of maintenance doses of caffeine citrate on tracheal tube removal and apnea after it in premature infants

## Public title

Comparison of the effectiveness of maintenance doses of caffeine citrate on tracheal tube removal and apnea after it in premature infants

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

Neonates with a gestational age of less than 35 weeks  
Hemodynamic stability during the first 48 hours after mechanical ventilation

### Exclusion criteria:

Neonates with congenital obstruction and perforation of the gastrointestinal tract  
Gastroschisis  
Congenital diaphragmatic hernia  
Cyanotic heart diseases  
Other congenital anomalies

## Age

From **1 day** old to **28 days** old

## Gender

Both

## Phase

2-3

## Groups that have been masked

- Participant
- Data analyser

## Sample size

Target sample size: **80**

Actual sample size reached: **80**

## Randomization (investigator's opinion)

Randomized

## Randomization description

The rand function of Excel software was used for randomization. Based on the random number obtained in the software, the babies are divided into two groups and this process will continue for each group up to 40 people.

## Blinding (investigator's opinion)

Single blinded

## Blinding description

In this study, the researcher is informed about the division of groups and the parents have received explanations about the research, but they are not informed about the division of groups. Also, the statistician does not know which data belong to the group with high dose of caffeine.

## Placebo

Not used

## Assignment

Parallel

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Kerman University of Medical Sciences

##### Street address

Imam highway

##### City

Kerman

##### Province

Kerman

##### Postal code

7616913555

#### Approval date

2023-01-17, 1401/10/27

#### Ethics committee reference number

IR.KMU.AH.REC.1401.247

## Health conditions studied

### 1

#### Description of health condition studied

Tracheal tube extubating and subsequent apnea in premature neonates

#### ICD-10 code

P28.4

#### ICD-10 code description

Other apnea of newborn

## Primary outcomes

### 1

#### Description

Tracheal extubation failure and subsequent apnea

#### Timepoint

During the hospitalization period

#### Method of measurement

Physical examination

## Secondary outcomes

### 1

#### Description

Tachycardia

#### Timepoint

Duration of treatment

#### Method of measurement

Cardiac monitoring

### 2

#### Description

Nutritional intolerance

#### Timepoint

Duration of treatment

**Method of measurement**

Physical examination

**3****Description**

Apnea of prematurity

**Timepoint**

Before and the end of the intervention

**Method of measurement**

Physical examination

**4****Description**

Duration of use of mechanical ventilation

**Timepoint**

Before and the end of the intervention

**Method of measurement**

Based on the questionnaire and file information

**5****Description**

Hospitalization period

**Timepoint**

Before and the end of the intervention

**Method of measurement**

Based on the questionnaire and file information

**6****Description**

Necrotizing enterocolitis

**Timepoint**

Before and the end of the intervention

**Method of measurement**

Clinical examination and abdominal imaging

**7****Description**

Ductus arteriosus remains open

**Timepoint**

Before and the end of the intervention

**Method of measurement**

Clinical examination and echocardiography

**Intervention groups****1****Description**

Intervention group: Caffeine citrate with an initial dose of 20 mg per kilogram of body weight per day and a maintenance dose of 10 mg per kilogram of body weight.

**Category**

Treatment - Drugs

**2****Description**

Control group: Caffeine citrate with an initial dose of 20

mg per kilogram of body weight per day and a maintenance dose of 5 mg per kilogram of body weight.

**Category**

Treatment - Drugs

**Recruitment centers****1****Recruitment center****Name of recruitment center**

Afzalipur Hospital

**Full name of responsible person**

Zahra Daei Parizi

**Street address**

Imam highway

**City**

Kerman

**Province**

Kerman

**Postal code**

7616913355

**Phone**

+98 34 3132 8000

**Email**

zdaei@kmu.ac.ir

**Sponsors / Funding sources****1****Sponsor****Name of organization / entity**

Kerman University of Medical Sciences

**Full name of responsible person**

Zahra Daei Parizi

**Street address**

Imam Highway

**City**

Kerman

**Province**

Kerman

**Postal code**

7616913355

**Phone**

+98 34 3132 8000

**Email**

zdaei@kmu.ac.ir

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Kerman University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Kerman University of Medical Sciences

**Full name of responsible person**

Zahra Daei Parizi

**Position**

Associate professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Pediatrics

**Street address**

Imam highway

**City**

Kerman

**Province**

Kerman

**Postal code**

7616913355

**Phone**

+98 34 3132 8000

**Email**

zdaeikmu.ac.ir

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Kerman University of Medical Sciences

**Full name of responsible person**

Zahra Daei Parizi

**Position**

Associate professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Pediatrics

**Street address**

Imam highway

**City**

Kerman

**Province**

Kerman

**Postal code**

7616913355

**Phone**

+98 34 3132 8000

**Email**

zdaeikmu.ac.ir

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Kerman University of Medical Sciences

**Full name of responsible person**

Zahra Daei Parizi

**Position**

Associate professor

**Latest degree**

Subspecialist

**Other areas of specialty/work**

Pediatrics

**Street address**

Imam highway

**City**

Kerman

**Province**

Kerman

**Postal code**

7616913355

**Phone**

+98 34 3132 8000

**Email**

zdaeikmu.ac.ir

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Not applicable

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

Its release schedule is not yet known

**When the data will become available and for how long**

Its release schedule is not yet known

**To whom data/document is available**

Its release schedule is not yet known

**Under which criteria data/document could be used**

Its release schedule is not yet known

**From where data/document is obtainable**

Its release schedule is not yet known

**What processes are involved for a request to access data/document**

Its release schedule is not yet known

**Comments**